Fisetin vs Resveratrol: The Longevity Polyphenol Comparison (2026)

Fisetin vs resveratrol: which longevity polyphenol has better evidence?

Fisetin and resveratrol are two of the best-known polyphenols in longevity supplementation, but they work through different mechanisms. Fisetin shows senolytic activity in selected preclinical models; systemic senescent-cell clearance in humans remains unproven [1]. Resveratrol was originally proposed as a sirtuin activator that mimics calorie restriction, though that specific mechanism has been debated for nearly two decades [2].

Resveratrol has a larger human trial literature with mixed findings; fisetin has preclinical senolytic activity and a smaller, heterogeneous body of human results without established systemic senescent-cell clearance. Neither compound is proven to extend human life, and clinical safety or added benefit from combining high doses has not been established. See our clinician's guide.

Read comparisons at the right evidence level. A positive mouse senolytic result for fisetin is not a human lifespan trial; a resveratrol insulin-sensitivity study cannot establish a fisetin effect. The broader human findings are summarized in our fisetin benefits review; because both are polyphenols with pharmacologic activities, the combination and medication safety discussion is also relevant. No clinical trial has established a healthspan benefit from combining the two.

What are fisetin and resveratrol, chemically?

Fisetin (3,3′,4′,7-tetrahydroxyflavone) is a flavonol — the same chemical subclass as quercetin. It's concentrated in strawberries and is derived commercially from smoke tree extract.

Resveratrol (3,5,4′-trihydroxystilbene) is a stilbene, a distinct polyphenol class. It's concentrated in red grape skins and Japanese knotweed root, from which it's commercially extracted. Resveratrol is the compound at the centre of the "French paradox" hypothesis — the observation that moderate red wine consumption in French populations correlates with lower cardiovascular mortality despite a high-fat diet.

Both are polyphenolic antioxidants with anti-inflammatory activity, and both have poor oral bioavailability. Their differences lie in their specific downstream targets.

How do the mechanisms differ — senolytic vs sirtuin activator?

Fisetin: senolytic

The 2018 Yousefzadeh paper established senolytic activity for fisetin in selected experimental systems [1]. Those findings support a mechanistic senolytic classification in preclinical research but do not establish systemic senescent-cell clearance in people. See our dedicated senolytic article for the mechanism in detail.

Resveratrol: a contested sirtuin activator

Resveratrol's original claim to fame was as a sirtuin activator — specifically, activating SIRT1 to produce calorie-restriction-like effects. Baur's landmark 2006 paper reported that high-dose resveratrol improved health and survival in mice on a high-calorie diet [2], proposed to work through SIRT1 activation. This launched more than a decade of research interest and repeated attempts to replicate the finding.

The direct-SIRT1-activation mechanism has since been extensively contested. Several groups have failed to replicate direct SIRT1 activation in cell-free assays, and some of the originally observed activation may reflect assay artefacts rather than a genuine biological effect. Alternative mechanisms have been proposed, including AMPK activation, direct antioxidant activity, and effects on mitochondrial biogenesis. The honest summary is that resveratrol has real biological activity, but its "sirtuin activator" identity is more contested and less settled than early coverage suggested.

What does the human evidence show for resveratrol?

Resveratrol has been studied in far more human trials than fisetin — but the honest picture includes real null results, not just positive ones.

A small positive trial

Timmers and colleagues randomised 11 obese men to 150 mg/day resveratrol or placebo for 30 days [3]. This small trial found genuine improvements: activated AMPK, increased SIRT1 and PGC-1α protein levels in muscle, improved mitochondrial respiration, lower circulating glucose and triglycerides, reduced inflammation markers, and improved blood pressure and insulin sensitivity index. It's one of the more encouraging resveratrol trials in humans, though the sample size is very small.

A trial that found no effect

A separate, larger trial randomised 24 obese men to high-dose resveratrol or placebo for four weeks [4]. Contrary to how this trial is sometimes summarised, its own results were null across the board: insulin sensitivity (the primary outcome) did not improve, and there was no effect on blood pressure, resting energy expenditure, fat oxidation, visceral or liver fat, or inflammatory and metabolic biomarkers. The authors themselves concluded that the lack of effect "raises doubt about the justification of resveratrol as a human nutritional supplement in metabolic disorders." This is a genuinely negative trial, not a "modest improvement" — an honest comparison has to include it as such.

The broader trial picture

A 2017 review of resveratrol clinical trials found that across neurological, cardiovascular, and diabetes trials, resveratrol was generally well tolerated and beneficially influenced disease biomarkers, but that its effects in certain cancers and in non-alcoholic fatty liver disease were ambiguous or even unfavourable, with poor bioavailability a recurring obstacle throughout [5]. The scale of the resveratrol clinical evidence is genuinely larger than fisetin's, but the signal across that evidence is inconsistent rather than uniformly positive.

The Dipak Das affair

In 2012, the University of Connecticut announced that Dipak Das, a prominent resveratrol researcher who had published extensively on its cardioprotective effects, had committed research misconduct. The university's investigation found evidence of fabricated or falsified data across more than 20 of his papers, and a number of journals subsequently issued retractions. This didn't invalidate the broader resveratrol literature, since Das's papers are a small fraction of the total, but it's a documented case worth naming: the scale of commercial and public interest in resveratrol created real incentives for both honest overreach and outright fraud in parts of the field.

Fisetin's current human evidence

Fisetin has a smaller and more heterogeneous human evidence base, including registered studies and a few completed trials with available results. Some findings have been inconclusive or negative and none validates systemic senescent-cell clearance as a clinical intervention. AFFIRM remains unreported [6], but it is inaccurate to describe all human fisetin trial data as pending.

How do the typical doses compare?

Aspect	Fisetin	Resveratrol
Mechanism	Candidate senolytic (preclinical clearance; human systemic clearance unproven)	Contested sirtuin activator; also implicated in AMPK activation and mitochondrial biogenesis
Typical daily dose	100–500 mg (continuous) or 20 mg/kg pulsed	150–500 mg daily, continuous (some trials used higher doses)
Bioavailability	Poor absorption, low plasma peaks	Good intestinal absorption but extensive first-pass metabolism, so parent-compound bioavailability is under 1%
Peer-reviewed human RCT with a functional endpoint	Limited human findings; systemic senolytic benefit unproven	Multiple, with mixed results — some positive, some entirely null on their own primary outcome
Notable controversy	None documented	2012 research-misconduct case (Dipak Das) affecting part of the mechanistic literature

When might you choose one over the other?

If you want a targeted senolytic effect, fisetin is the more direct mechanistic choice — resveratrol has no established senolytic activity. If cardiometabolic endpoints such as insulin sensitivity or mitochondrial biomarkers are your priority, resveratrol has a longer human trial history, though you should weigh the positive Timmers-style findings against genuinely null trials like Poulsen's rather than assuming a uniform benefit. If you're weighing total volume of human data, resveratrol has more; if you want a more mechanistically specific bet with less baggage, fisetin's narrower evidence base is at least more focused, even though it's still pending its own human validation.

Is it safe to combine fisetin and resveratrol?

The combination has not been adequately tested in controlled human interaction or outcome studies. Different proposed mechanisms do not establish that their effects are additive, that their metabolic pathways never overlap, or that taking both at concentrated doses is safe. Resveratrol and fisetin each undergo extensive metabolism, and co-use with prescription medicines may introduce additional uncertainty.

No validated combined dose, timing or schedule exists. Neither a shared meal nor a monthly fisetin pulse should be presented as an evidence-based combination protocol. Review specific products and medicines with a clinician or pharmacist before combining high-dose supplements.

Further reading: fisetin's formulation-specific pharmacokinetic evidence; the separate fisetin–quercetin comparison. Overlapping laboratory pathways alone cannot establish comparative human effectiveness.

What we still don't know

Whether resveratrol has any true SIRT1-independent longevity effect in humans — the mechanism debate remains unresolved.

Whether fisetin's AFFIRM trial, when it publishes, will give fisetin its first randomised human senolytic-outcome data and meaningfully shift this comparison.

Whether combining fisetin and resveratrol produces any additive human benefit — not tested in any trial.

Why resveratrol's positive small trials (like Timmers) haven't consistently replicated in larger or differently designed studies (like Poulsen) — dose, population, and duration differences are plausible explanations, but this isn't resolved.

Bottom line

Fisetin and resveratrol are different polyphenols with different research histories. Resveratrol has more human trials but inconsistent results, while fisetin has preclinical senolytic activity and limited heterogeneous human findings without validated systemic senescent-cell clearance. Neither is proven to extend human lifespan. There is no adequately controlled human evidence that combining their concentrated forms is safe, improves exposure or adds clinical benefit. See our clinician's guide.